News | August 16, 2022
QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Man lost 54 Kgs in 6 months with MGB procedure
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
The product will be manufactured at Lupin’s facility in Goa, India.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
New deal strengthens Congenica’s presence in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
